Hematology prior authorization at Horizon Blue Cross Blue Shield of New Jersey
PA workflow, documentation criteria, and peer-to-peer prep — for prescribers and PA staff
Horizon Blue Cross Blue Shield of New Jersey hematology PA at a glance
Horizon Blue Cross Blue Shield of New Jersey reviews hematology PA submissions against its medical policy library, with rules drawn primarily from NCCN + ASH (American Society of Hematology). Horizon Blue Cross Blue Shield of New Jersey-specific context: Only BCBS licensee in New Jersey; ~3.7M members. OMNIA Health Plans (tiered network) generate frequent appeals — tier-2 hospital usage carries higher cost share. NJ DOBI oversight; NJ has a strong external review program (IHCAP via Maximus).
Documentation packet — what to send
- Diagnosis with ICD-10 (CLL, MM, NHL, etc.)
- Stage / risk stratification
- Molecular markers (BCR-ABL, TP53, IGHV, FISH)
- Prior lines of therapy with response
- Performance status
Common denial patterns to pre-empt
Patterns observed in hematology across payers, and where Horizon Blue Cross Blue Shield of New Jersey's book of business overlaps:
- Off-label use (e.g., rituximab for non-Hodgkin's vs autoimmune)
- Indication-specific dosing
- Genetic testing (BCR-ABL, BRAF, TP53) not documented
- Step therapy in CLL / lymphoma
- Site of service for infusion
- Step therapy on biologics
Appeal angles when Horizon Blue Cross Blue Shield of New Jersey denies
- NCCN Compendium citation for hematologic malignancy
- Molecular / cytogenetic test results supporting indication
- Performance status documentation
- Documented response/failure of prior lines
Peer-to-peer prep
- Bring the molecular pathology report
- Quote NCCN Compendium category (1, 2A, 2B)
- Reference the pivotal trial for the prescribed regimen
- Document prior-line response (CR, PR, SD, PD) explicitly
Drug-specific PA criteria at Horizon Blue Cross Blue Shield of New Jersey
Deep dives on each drug's PA criteria at Horizon Blue Cross Blue Shield of New Jersey:
Frequently asked questions
What documentation does Horizon Blue Cross Blue Shield of New Jersey need for hematology prior authorizations?
Horizon Blue Cross Blue Shield of New Jersey's PA packet for hematology typically includes: Diagnosis with ICD-10 (CLL, MM, NHL, etc.); Stage / risk stratification; Molecular markers (BCR-ABL, TP53, IGHV, FISH); Prior lines of therapy with response. NCCN + ASH (American Society of Hematology) citations strengthen the submission.
What's the turnaround at Horizon Blue Cross Blue Shield of New Jersey?
Horizon Blue Cross Blue Shield of New Jersey standard decision: 30 days. Expedited (urgent care): 72 hours per 45 CFR §147.136. Internal appeal window if denied: 180 days.
Which hematology drugs does Horizon Blue Cross Blue Shield of New Jersey most often PA-restrict?
Top targets in hematology: rituximab, imatinib, ibrutinib, lenalidomide, apixaban. Each follows the per-drug step therapy + documentation requirements published in Horizon Blue Cross Blue Shield of New Jersey's medical policy library.
How do I prep a peer-to-peer with Horizon Blue Cross Blue Shield of New Jersey in hematology?
Bring the molecular pathology report Quote NCCN Compendium category (1, 2A, 2B) Have the policy URL and the patient's chart open before the call.
Generate a Hematology PA packet
Open ApprovalHelp — generate a hematology PA packet tailored to Horizon Blue Cross Blue Shield of New Jersey's criteria, with prescriber attestation and supporting citations pre-filled.
Get started →Contact: hello@approvalhelp.com